DDInter833 DDInter1601
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Ripretinib
Glycerol phenylbutyrate (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Glycerol phenylbutyrate (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Ripretinib